Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in Moderate, Severe, or Critical COVID-19 (CORIMUNO-SARI)
NCT04324073Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2020
- Primary completion
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sarilumab in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population, Percentage of Participants With Non-invasive Ventilation, Mechanical Ventilation or Death at Day 14 -- Severe COVID Population and 2 more. Started Mar 2020; status: completed.
02
Drugs
sarilumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04324073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04324073.